Efgartigimod
argenx
['7 & 8']
#ash22
paper 3 - c. broome et al. compared to placebo, efgartigimob showed an early platelet increase and higher sustained platelet response in patients with primary immune thrombocytopenia. a new safe and efficient treatment option for patients with immune thrombocytopenia! 
Hematologist at Saint Antoine Hospital, Paris, France @Sorbonne_Univ_ @APHP. @JACIE_EBMT National Representative. #BMTsm #LYMsm #CARTcell #CardioOnc #QoL